WINTON GROUP Ltd Acquires 66,200 Shares of Syndax Pharmaceuticals, Inc. $SNDX

WINTON GROUP Ltd boosted its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 642.7% during the 2nd quarter, Holdings Channel reports. The firm owned 76,500 shares of the company’s stock after acquiring an additional 66,200 shares during the period. WINTON GROUP Ltd’s holdings in Syndax Pharmaceuticals were worth $1,672,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of SNDX. Jupiter Topco LLC bought a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth $860,000. Orbimed Advisors LLC purchased a new position in shares of Syndax Pharmaceuticals in the 1st quarter worth about $22,479,000. Eventide Asset Management LLC grew its position in Syndax Pharmaceuticals by 25.3% during the fourth quarter. Eventide Asset Management LLC now owns 1,238,196 shares of the company’s stock valued at $26,014,000 after buying an additional 249,710 shares during the period. Hennion & Walsh Asset Management Inc. grew its position in Syndax Pharmaceuticals by 59.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 342,883 shares of the company’s stock valued at $7,495,000 after buying an additional 128,076 shares during the period. Finally, Apis Capital Advisors LLC increased its holdings in Syndax Pharmaceuticals by 13.5% during the fourth quarter. Apis Capital Advisors LLC now owns 724,000 shares of the company’s stock worth $15,211,000 after buying an additional 86,000 shares during the last quarter.

Insider Buying and Selling at Syndax Pharmaceuticals

In other news, CEO Michael Metzger sold 32,375 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $24.24, for a total value of $784,770.00. Following the sale, the chief executive officer owned 484,843 shares of the company’s stock, valued at $11,752,594.32. The trade was a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.80% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have commented on the stock. HC Wainwright lowered their price objective on shares of Syndax Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Bank of America reissued a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, August 5th. JPMorgan Chase & Co. decreased their price target on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. UBS Group lowered their price target on shares of Syndax Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating on the stock in a report on Friday, August 21st. Finally, Weiss Ratings upgraded Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 21st. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.30.

Syndax Pharmaceuticals Trading Down 3.4%

Shares of SNDX opened at $18.18 on Friday. The business has a 50-day moving average of $20.74 and a 200 day moving average of $21.22. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $12.99 and a fifty-two week high of $25.59. The firm has a market cap of $1.61 billion, a P/E ratio of -7.24 and a beta of 0.37. The company has a debt-to-equity ratio of 38.95, a quick ratio of 6.44 and a current ratio of 6.77.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The business had revenue of $72.79 million for the quarter, compared to analysts’ expectations of $79.36 million. Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. Syndax Pharmaceuticals’s revenue for the quarter was up 91.8% compared to the same quarter last year. During the same period last year, the company earned ($0.83) earnings per share. As a group, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for cancer and other serious diseases. The company’s research has centered on medicines that target disease-driving biological pathways, including genetically defined forms of leukemia and immune-related conditions.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved by the U.S. Food and Drug Administration for certain adults and children with relapsed or refractory acute leukemia involving a KMT2A translocation.